Oral Solid Dosage Contract Manufacturing Market

Market Outlook

The global oral solid dosage contract manufacturing market, valued at USD 23.4 billion in 2025, is projected to reach USD 24.6 billion in 2026 and USD 39.4 billion by 2035, with a CAGR of 5.39% during the forecast period 2026 to 2035.

Market Report: Key Takeaways

Market Size and Trends

• In terms of type of finished dosage form, tablets account for the highest share (more than 70%) of the market in 2026.
• Based on the type of packaging, bottles are likely to occupy the largest share of the market in 2035.
• In terms of scale of operation, commercial scale captures the highest share of the market in 2026.
• Based on company size, large companies dominate the current market, accounting for highest market share (more than 80%) in 2026.
• Based on type of release mechanism, modified release segment is likely to capture the majority share of the market, by 2035.
• Based on therapeutic areas, oncological disorders capture the largest oral solid dosage contract manufacturing market share in 2026.
• In terms of geographical regions, North America is expected to dominate the oral solid manufacturing industry by securing nearly 50% of the market share in future.

Market Introduction

The rising complexity of active pharmaceutical ingredients (APIs) has led to the development of a myriad of novel formulations aimed at improving drug delivery to the specific site of action. Despite these advancements, oral solid dosage (OSD) forms, such as tablets and capsules continue to hold a dominant position in the global pharmaceutical market. Further, it is important to mention that over two-thirds of the total drugs prescribed worldwide are dispensed in the form of oral solid dose pharmaceuticals. This is due to various advantages offered by them, such as cost-effectiveness, better patient convenience and high stability which are essential for improving medication adherence.

Driven by ongoing innovations, drug developers are focusing on the development of advanced oral formulations, such as modified disintegrating tablets (ODTs), drug device combination products and sustained release dosage forms, that can improve API solubility and enhance bioavailability. However, the manufacturing of these oral solid doses (especially those containing highly potent APIs) is a complex and research-intensive process. It demands specialized expertise for various processes spanning from formulation development to commercial scale-up manufacturing. In order to meet the growing demand, the drug developers are relying on specialized contract service providers to navigate operational challenges, including complex formulations, strict regulations and supply chain challenges.

Market Segmentation

Based on our secondary research, we have segmented the Oral Solid Dosage Contract Manufacturing Market into type of finished dosage form, type of packaging, scale of operation, company size, type of release mechanism, therapeutic area and geographical regions.

Market by Type of Finished Dosage Form

• Tablets
• Capsules
• Other Finished Dosage Forms

Market by Type of Packaging

• Bottles
• Blisters
• Other Types of Packaging

Market by Scale of Operation

• Commercial Scale
• Clinical Scale

Market by Company Size

• Large Companies
• Mid-Sized Companies
• Small Companies

Market by Type of Release Mechanism

• Immediate Release Formulations
• Modified Release Formulations

Market by Therapeutic Area

• Oncological Disorders
• Cardiovascular Disorders
• Infectious Diseases
• Neurological Disorders
• Diabetes
• Respiratory Disorders
• Immunological Disorders
• Genetic Disorders
• Rare Diseases
• Other Disorders

Market by Geographical Regions

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and North Africa

Key Market Insights

What Factors are Driving Increased Adoption of Oral Solid Formulations?

• Emergence of Virtual Pharmaceutical Companies: The growing emergence of virtual pharmaceutical oral solid dosage manufacturing companies is fueling expansion in the oral solids market. Such companies outsource key operations, including formulation, manufacturing and testing to specialized partners, enabling accelerated development and reduced operational costs. As a result, contract development and manufacturing organizations (CDMOs) are witnessing rising demand for expertise in tablet and capsules production.
• Growing Demand for Novel Oral Solid Formulations: The oral solid dose manufacturing market is experiencing strong growth due to rising demand for innovative and more effective formulations, such as digital pills, 3D printed drugs and amorphous solid dispersions. Notably, patients and healthcare providers are consistently looking for oral solids (including tablets and capsules) with improved bioavailability, controlled release and easier administration. Pharmaceutical companies are proactively investing in cutting-edge technologies to meet these demands.

Recent Developments in OSD Pharmaceutical Manufacturing Market

• In April 2026, Jamjoom Pharma signed an agreement to acquire Pfizer's OSD manufacturing site in King Abdullah Economic City, Saudi Arabia. The acquisition aims to aid Jamjoom Pharma in increasing its manufacturing capacity and strengthen its supply chain, by integrating the facility into its existing manufacturing network, while maintaining high quality standards and supporting the current workforce.
• In February 2026, Bora Pharmaceuticals signed a USD 250 million strategic agreement to renew a five-year manufacturing partnership. This renewed collaboration reinforces the long-standing relationship between the two companies and expands the partnership, allowing GSK access to multiple sites within the Bora network, including its newest oral solid dose (OSD) site in Maple Grove, Minnesota.
• In February 2026, Bora Pharmaceuticals and Corealis Pharma formed a strategic alliance to speed the development of oral solid dose medicines. Through this partnership, Corealis aims to focus on early-stage formulation development and clinical trial supply, while Bora Pharmaceuticals is likely to provide large scale manufacturing and regulatory support.

Industry Experts on Oral Solid Dosage Contract Manufacturing Market

The market for oral solids has a transformative future and is likely to remain progressive over the next decade. Highlighting this trend, Shahrzad Missaghi (Senior Manager, Product Development, Colorcon), stated, “We are aware, oral solid dosages are really on the rise, and this trend is likely to keep going past 2025 due to their ease of administration and support in patient compliance. With increasing population and people having longer lifespans, the demand keeps on increasing. At the same time, we are witnessing a big shift toward digitalization and using AI across discovery, formulation, manufacturing, and even clinical trials to make everything faster and smarter.”

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The oral solid dosage contract manufacturing market report features detailed transcripts of interviews conducted with the following individuals:

• Senior Executive Director of Global Sales and Marketing, Large Company, Japan

In addition, the market report includes transcripts of the following other third-party discussions:

• Director and Technology Head, Very Large Company, Switzerland
• Vice President and Chief Innovation Officer, Large Company, US
• Vice President, R&D and Regulatory Submission, Mid-Sized Company, US
• Vice President, Drug Product Division, Very Large Company, US
• Vice President Technology Transfer, Very Large Company, India
• Head of Product Implementation, Oral Solid Dose, Large Company, Sweden
• Head of Global Pharmaceutical Sciences, Large Company, France
• Business Development Manager, Large Company, Germany
• Co-Team Leader, Mid-Sized Company, US
• Scientific Content Director, Mid-Sized Company, US

Market Share Insights

Which Finished Dosage Form Holds the Largest Share of Oral Solid Dosage Contract Manufacturing Market?

• In 2035, the tablets segment is likely to occupy the highest (more than 70%) oral solid dosage contract manufacturing market share. This is primarily due to lower manufacturing costs and longer shelf life offered by tablets. Additionally, various delivery types (long acting drugs, such as extended release, delayed release) of tablets caters to expand their market potential.
• The capsules segment is expected to witness a higher CAGR in the future, driven by the growing adoption of highly potent active pharmaceutical ingredients (HPAPIs), increasing complexity of drug molecules, and the industry’s shift toward patient-centric, flexible and targeted drug delivery systems.

Regional Market Analysis: Which Regions are Showing the Fastest Growth?

North America: Dominating the Market by Securing Highest Share

North America is likely to capture nearly 50% of the OSD contract manufacturing market share in 2035, owing to rising commercial demand for oral solid dosage pharmaceuticals in the US and presence of well-established oral solid dosage manufacturers in this region. Further, in recent years, many large oral solid dosage manufacturing companies within this region have expanded their capabilities to meet the growing demand in this region.

Europe: Driving the Future of Market Expansion

• In Europe, the market is likely to grow at a higher CAGR till 2035, driven by a growing investment in R&D of new drugs and stringent regulatory requirements that favor specialized manufacturers. Moreover, the growing demand for generic drugs driven by patent expirations in the region, along with the pharmaceutical industry's increasing dependence on CDMOs for cost efficiency and specialized expertise, has further accelerated the solid dose CDMO market growth.

Oral Solid Dosage Contract Manufacturing Market: Scope of the Report

Frequently Asked Questions